IP Library Granted Patent US 9,974,692
Granted Patent B2
US 9,974,692 · App. 15/412,980 · Granted May 22, 2018

System and method for femto-fragmentation of a crystalline lens

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,974,692
App. No.
15/412,980
Granted
May 22, 2018
Kind
B2
Abstract

A system and method for performing a femto-fragmentation procedure on tissue in the crystalline lens of an eye requires that a laser beam be directed and focused to a focal point in the crystalline lens of the eye. The focal point is then guided, relative to an axis defined by the eye, to create a segment cluster by causing Laser Induced Optical Breakdown (LIOB) of tissue in the crystalline lens. The resultant segment cluster includes a plurality of contiguous, elongated segments in the crystalline lens that are individually tapered from an anterior end-area to a posterior end-area. Specifically, this is done to facilitate the removal of individual segments from the segment cluster in the crystalline lens.

Claims (25)

1. A system for performing a femto-fragmentation lensectomy procedure on tissue in the crystalline lens of an eye which comprises:

a laser unit for generating a laser beam;

a computer connected with the laser unit for directing the laser beam along a beam path to a focal point in the crystalline lens of the eye wherein the lens has a thickness and defines an axis, and the beam path and the focal point are established relative to the axis defined by the lens;

a computer generated template pattern, wherein the template pattern is oriented relative to the axis;

a controller connected with the computer for moving the focal point relative to the axis defined by the lens, to cause a Laser Induced Optical Breakdown (LIOB) of tissue in the crystalline lens at the focal point to create a plurality of contiguous, elongated, individual segments in the crystalline lens, wherein each individual segment is aligned axially in the lens and individually extends through a length of approximately 80% of the thickness of the lens between a respective anterior end area characterized by a dimension “s a ”, and a respective posterior end-area characterized by a corresponding dimension “s p ”, and wherein each segment is tapered from the anterior end-area toward the posterior end-area (“s a ”>“s p ”);

and an aspirator for sequentially removing the-created individual segments of the crystalline lens from the eye.

2. The system recited in claim 1 wherein the anterior end-area is shaped as a rectangle and the characteristic dimension “s a ” of the anterior end-area is a side distance of the rectangle.

3. The system recited in claim 2 wherein the characteristic dimension “s a ” is less than three hundred and fifty microns (s a <350 μm).

4. The system recited in claim 1 wherein the anterior end-area is a square.

5. The system recited in claim 1 wherein the characteristic dimension “s p ” of the posterior end-area is less than ninety percent of the characteristic dimension “s a ” of the anterior end-area (s p <0.9s a ).

6. The system recited in claim 1 wherein the crystalline lens has an exterior surface, and a predetermined volume of tissue, and wherein the tissue for LIOB within the crystalline lens is more than a selected distance from the exterior surface of the crystalline lens to establish a safety margin therebetween.

7. The system recited in claim 6 wherein the safety margin is greater than approximately 50 microns.

8. A system for performing a femto-fragmentation fensectomy procedure on tissue in the crystalline lens of an eye which comprises:

a laser unit for directing a laser beam along a beam path to a focal point in the crystalline lens of the eye, wherein the lens has a thickness and defines an axis and the beam path and the focal point are established relative to the axis defined by the lens;

a template having a template pattern for defining a plurality of contiguous, elongated, individual segments in the crystalline lens wherein each individual segment is aligned axially in the lens and individually extends through a length of approximately 80% of the thickness of the lens between a respective anterior end-area characterized by a dimension “s a ”, and a respective posterior end-area characterized by a corresponding dimension “s p ”, and wherein each segment is tapered from the anterior end-area toward the posterior end-area (“s a ”>“s p ”);

a computer connected to the laser unit for guiding the focal point of the laser beam with reference to the axis and to a computer-generated template pattern to cause a Laser Induced Optical Breakdown (LIOB) of tissue in the crystalline lens at the focal point; and

an aspirator for sequentially removing the plurality of individual segments of the crystalline lens from the eye.

9. The system recited in claim 8 wherein the template pattern is oriented relative to the axis and the focal point of the laser beam is moved in accordance with the template pattern.

10. The system recited in claim 8 wherein the anterior end-area is shaped as a rectangle and the characteristic dimension “s a ” of the anterior end-area is a side distance of the rectangle.

11. The system recited in claim 10 wherein the anterior end-area is a square.

12. The system recited in claim 11 wherein the characteristic dimension “s a ” is less than three hundred and fifty microns (s a <350 μm).

13. The system recited in claim 8 wherein the anterior end-area is shaped as a triangle.

14. The system recited in claim 8 wherein the characteristic dimension “s p ” of the posterior end-area is less than ninety percent of the characteristic dimension “s a ” of the anterior end-area (s p <0.9s a ).

15. The system recited in claim 8 wherein the crystalline lens has an exterior surface and a predetermined volume of tissue within the crystalline lens, wherein the predetermined volume of tissue is more than a selected distance from the exterior surface of the crystalline lens to establish a safety margin therebetween.

16. The system recited in claim 15 wherein the safety margin is greater than approximately 50 microns.

Assignments (19)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (059913/0548) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072469/0091 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
PATENT SECURITY AGREEMENT Recorded Oct 4, 2023
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 065120/0086 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 048556/0758) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH COMPANIES INC.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0484 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 056811/0814) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061872/0669 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 059121/0001) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061873/0001 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
PATENT SECURITY AGREEMENT Recorded May 10, 2022
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A. AS COLLATERAL AGENT
Reel/Frame 059913/0548 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2017
From: GOH, TOH SENG; MCCARY, BRIAN D.; MORDAUNT, DAVID HAYDN
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 041327/0207 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2017
From: LOESEL, FRIEDER; KANDULLA, JOCHEN; YOUSSEFI, GERHARD; BANGHARD, WERNER
To: TECHNOLAS PERFECT VISION GMBH
Reel/Frame 041327/0358 →